MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
EPIX - Essa Pharma Inc
$13.82
0.14(1.02%)6:00:01 PM 11/26/2021
ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • RSI is at a high level of 77. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap444.3M
PE Ratio
PEG Ratio
P/B5.4
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %0%
Held by Institutions %77%
1 Day Vol Adjusted Return0.2
1 Month Vol Adjusted Return11.3
3 Month Vol Adjusted Return9.8
6 Month Vol Adjusted Return-12.6
20 Days SMA Price ZScore1.4
50 Days SMA Price ZScore2.1
12 -26 Days PPO9.6
1 Month Average Short Volume Ratio39.5
1 Day Volume Change ZScore-1.1
1 Month Daily Vol4.9
Related Topics
leak data

Related Topics

Stock news

    11/22/2021EPIX
    EPIX: Combination Studies Set to Initiate…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen

    11/18/2021EPIX
    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

    11/8/2021EPIX
    ESSA Pharma to Participate in Three Upcoming Investor Conferences

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the o

    10/28/2021EPIX
    ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.

    10/19/2021EPIX
    Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX)

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

    10/7/2021EPIX
    ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact

    Caris Life Sciences and ESSA Pharma Inc (NASDAQ: EPIX) have announced a Precision Development program to support ESSA's development of EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) failing current standard-of-care therapies. Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing and Whole Exome Sequencing platform. ESSA will utilize these liquid biopsies, including longi

    10/7/2021EPIX
    ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. The data include the results of nuclear magnetic resonance (NMR) studies which confirm the binding of the compound to the N-terminal domain (NTD) of th